{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:27:59Z","timestamp":1790051279415,"version":"4.0.1"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The immunomodulatory enzyme, indoleamine 2,3-dioxygenase (IDO) facilitates tryptophan catabolism at the rate-limiting step of the kynurenine (Kyn) pathway. IDO expression and elevations in Kyn metabolites are associated with immunosuppressive tumor microenvironment including T cell proliferative arrest and generation of regulatory T cells (Tregs) which can favor tumor progression. However, the extent of the role of IDO in acute myeloid leukemia (AML) is currently ill-defined. This study reviews the role of IDO-driven Treg function in AML and evaluates the current body of evidence implicating IDO in AML pathogenesis.<\/jats:p><jats:p><jats:bold>Method:<\/jats:bold> Studies related to IDO in AML were identified through a systematic review of PubMed and Scopus. Data extracted described sample analysis, IDO expression, IDO in prognosis, techniques used in Treg phenotypic studies, and the effect of IDO inhibitors.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Twenty studies were included in the systematic review. Expression of IDO was identified in a range of cells in AML, both inducible and constitutive. Seven studies indicated an association between elevated expression and poor clinical prognosis. Six studies suggested a positive correlation between IDO expression and Treg induction, with FoxP3 being the prominent Treg phenotypic marker. Of eight studies investigating IDO inhibition, some reported reductions in Treg frequency and enhanced effector T cell proliferation.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This review highlights that IDO expression in AML is associated with poor prognosis and measurement of IDO and its Kyn metabolites may offer utility as prospective prognostic markers. Pharmacological inhibition of IDO using novel drugs may hold promise for the treatment of AML.<\/jats:p>","DOI":"10.3389\/fimmu.2021.651687","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T06:16:29Z","timestamp":1615356989000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Investigating the Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia: A Systematic Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Georgia","family":"Wells","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekh N.","family":"Dahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.blre.2016.08.005","article-title":"Molecular biomarkers in acute myeloid leukemia","volume":"31","author":"Prada-Arismendy","year":"2017","journal-title":"Blood Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/cncr.22233","article-title":"Acute myeloid leukemia: epidemiology and etiology","volume":"107","author":"Deschler","year":"2006","journal-title":"Cancer."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.3390\/ijms18122577","article-title":"Acute myeloid leukaemia: new targets and therapies","volume":"18","author":"Brown","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/jim-2018-000807","article-title":"New and emerging therapies for acute myeloid leukaemia","volume":"66","author":"Davis","year":"2018","journal-title":"J Invest Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S0140-6736(12)61727-9","article-title":"Acute myeloid leukaemia in adults","volume":"381","author":"Ferrara","year":"2013","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1365-2141.2004.05236.x","article-title":"Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis?","volume":"128","author":"Reilly","year":"2005","journal-title":"Br J Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/CCO.0b013e32833118fd","article-title":"FLT3 inhibition as a targeted therapy for acute myeloid leukemia","volume":"21","author":"Sanz","year":"2009","journal-title":"Curr Opin Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/1535-7163.Mct-16-0876","article-title":"FLT3 inhibitors in acute myeloid leukemia: current status and future directions","volume":"16","author":"Larrosa-Garcia","year":"2017","journal-title":"Mol Cancer Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1200\/jco.2006.06.5037","article-title":"Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98","volume":"24","author":"Creutzig","year":"2006","journal-title":"J Clin Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"key":"B11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.critrevonc.2016.04.020","article-title":"Harnessing the immune system in acute myeloid leukaemia","volume":"103","author":"Austin","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"294","DOI":"10.5045\/br.2018.53.4.294","article-title":"Overexpression of indoleamine 2,3-dioxygenase correlates with regulatory T cell phenotype in acute myeloid leukemia patients with normal karyotype","volume":"53","author":"Arandi","year":"2018","journal-title":"Blood Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1002\/eji.201242572","article-title":"Indoleamine 2,3-dioxygenase: from catalyst to signaling function","volume":"42","author":"Fallarino","year":"2012","journal-title":"Eur J Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1471-4906(03)00072-3","article-title":"Tolerance, DCs and tryptophan: much ado about IDO","volume":"24","author":"Grohmann","year":"2003","journal-title":"Trends Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1158\/0008-5472.CAN-12-0569","article-title":"Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion","volume":"72","author":"Platten","year":"2012","journal-title":"Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/imcb.1003","article-title":"Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells","volume":"96","author":"Sasidharan Nair","year":"2018","journal-title":"Immunol Cell Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/10245332.2015.1106814","article-title":"Indoleamine 2,3-dioxygenase and regulatory T cells in acute myeloid leukemia","volume":"21","author":"Mansour","year":"2016","journal-title":"Hematology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.18632\/oncotarget.1504","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia","volume":"5","author":"Folgiero","year":"2014","journal-title":"Oncotarget."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3109\/10428194.2014.953150","article-title":"Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics","volume":"56","author":"Fukuno","year":"2015","journal-title":"Leuk Lymphoma."},{"key":"B21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.leukres.2008.06.014","article-title":"Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-\u03b3","volume":"33","author":"Corm","year":"2009","journal-title":"Leuk Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"12892","DOI":"10.1038\/s41598-017-12940-0","article-title":"A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression","volume":"7","author":"Mangaonkar","year":"2017","journal-title":"Sci Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s12032-010-9459-6","article-title":"Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells","volume":"28","author":"El Kholy","year":"2011","journal-title":"Med Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/blood-2006-07-036863","article-title":"Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25\u2212 into CD25+ T regulatory cells","volume":"109","author":"Curti","year":"2006","journal-title":"Blood."},{"key":"B25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3109\/10428194.2015.1041388","article-title":"High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia","volume":"57","author":"Mabuchi","year":"2016","journal-title":"Leuk Lymphoma."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3324\/haematol.2010.025924","article-title":"Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells","volume":"95","author":"Curti","year":"2010","journal-title":"Haematologica."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.3109\/10428194.2015.1128541","article-title":"Prognostic value of the combination of serum l-kynurenine level and indoleamine 2,3-dioxygenase mRNA expression in acute myeloid leukemia","volume":"57","author":"Hara","year":"2016","journal-title":"Leuk Lymphoma."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3324\/haematol.13112","article-title":"High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome","volume":"93","author":"Martine","year":"2008","journal-title":"Haematologica."},{"key":"B29","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jpba.2019.01.022","article-title":"Identification of novel serum biomarker for the detection of acute myeloid leukemia based on liquid chromatography-mass spectrometry","volume":"166","author":"Wang","year":"2019","journal-title":"J Pharma Biomed Anal."},{"key":"B30","first-page":"8605","article-title":"Expression of indoleamine 2,3-dioxygenase in acute leukemic cells and the clinical significance","volume":"9","author":"Chen","year":"2016","journal-title":"Int J Clin Exp Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/sj.leu.2404485","article-title":"Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase","volume":"21","author":"Curti","year":"2007","journal-title":"Leukemia."},{"key":"B32","doi-asserted-by":"publisher","first-page":"253191","DOI":"10.1155\/2015\/253191","article-title":"PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response","volume":"2015","author":"Trabanelli","year":"2015","journal-title":"J Immunol Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-015-0134-4","article-title":"TIM-3\/Gal-9 interaction induces IFN\u03b3-dependent IDO1 expression in acute myeloid leukemia blast cells","volume":"8","author":"Folgiero","year":"2015","journal-title":"J Hematol Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"15010","DOI":"10.1074\/jbc.M110.103713","article-title":"Involvement of oxidative stress in the relapse of acute myeloid leukemia","volume":"285","author":"Zhou","year":"2010","journal-title":"J Biol Chem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.3389\/fimmu.2017.01918","article-title":"ATP release from chemotherapy-treated dying leukemia cells elicits an immune suppressive effect by increasing regulatory T cells and tolerogenic dendritic cells","volume":"8","author":"Lecciso","year":"2017","journal-title":"Front Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"10132","DOI":"10.3390\/molecules180910132","article-title":"Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells","volume":"18","author":"Iachininoto","year":"2013","journal-title":"Molecules."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.7150\/jca.31727","article-title":"Role of IDO and TDO in cancers and related diseases and the therapeutic implications","volume":"10","author":"Ye","year":"2019","journal-title":"J Cancer."},{"key":"B38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41417-018-0013-6","article-title":"Clinical and biological implications of mutational spectrum in acute myeloid leukemia of FAB subtypes M4 and M5","volume":"25","author":"Cheng","year":"2018","journal-title":"Cancer Gene Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-11-3687","article-title":"T-Regulatory cells: key players in tumor immune escape and angiogenesis","volume":"72","author":"Facciabene","year":"2012","journal-title":"Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nri3464","article-title":"The plasticity and stability of regulatory T cells","volume":"13","author":"Sakaguchi","year":"2013","journal-title":"Nat Rev Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s10753-012-9496-8","article-title":"CD4+CD25+CD127low\/\u2212 T cells: a more specific Treg population in human peripheral blood","volume":"35","author":"Yu","year":"2012","journal-title":"Inflammation."},{"key":"B42","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/cei.12091","article-title":"Indoleamine 2,3 dioxygenase contributes to transferable tolerance in rat red blood cell inducible model of experimental autoimmune haemolytic anaemia","volume":"173","author":"Dahal","year":"2013","journal-title":"Clin Exp Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1126\/science.281.5380.1191","article-title":"Prevention of allogeneic fetal rejection by tryptophan catabolism","volume":"281","author":"Munn","year":"1998","journal-title":"Science."},{"key":"B44","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.fct.2007.07.017","article-title":"Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption","volume":"46","author":"Jia","year":"2008","journal-title":"Food Chem Toxicol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40259-018-0291-4","article-title":"Indoleamine 2,3-dioxygenase (IDO) inhibition as a strategy to augment cancer immunotherapy","volume":"32","author":"Yentz","year":"2018","journal-title":"BioDrugs."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3389\/fimmu.2019.01801","article-title":"Limitations and off-target effects of tryptophan-related IDO inhibitors in cancer treatment","volume":"10","author":"G\u00fcnther","year":"2019","journal-title":"Front Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J Exp Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"B49","unstructured":"A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.2016"},{"key":"B50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4137\/CPath.S39930","article-title":"IDO2: a pathogenic mediator of inflammatory autoimmunity","volume":"9","author":"Merlo","year":"2016","journal-title":"Clin Med Insights Pathol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/intimm\/dxt073","article-title":"IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation","volume":"26","author":"Metz","year":"2014","journal-title":"Int Immunol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.651687\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T06:16:39Z","timestamp":1615356999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.651687\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,10]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2021.651687"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.651687","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,10]]},"article-number":"651687"}}